UCB drug first to be recommended in new NICE pathway

3 August 2021

The UK’s National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination recommending UCB’s (Euronext: UCB) bimekizumab as an option for adults with severe plaque psoriasis.

This recommendation is the first to follow the NICE’s new Expedited Low Risk Fast Track Appraisal process, a pathway developed in response to the COVID-19 pandemic to minimize delaying access to new innovative medicines.

"This fast-tracked NICE decision marks a significant moment for innovative medicines in the UK"As part of this process, a subset of the appraisal committee is able to make a recommendation based on the evidence included in the initial submission made by the company and assessed by the Evidence Review Group, without the need for a full committee meeting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK